It was not until 1972 that thymic carcinoids were recognized as distinct lesions and not as variants of thymomas. Carcinoid tumors are classified among the amine precursor uptake and decarboxylation tumors (APUDomas), which have the potential to produce several peptides, amines, kinins, and prostaglandins. Thymic carcinoid tumors are uncommon, and only about 250 cases have been reported in the world literature to date. In our case, the thymic carcinoid tumor was bigger (22×16×10cm) than those described before. The use of immunohistochemical studies permitted a more accurate differentiation and diagnosis of this tumor. The treatment and prognosis are reported herein. Treatment included surgical excision for a complete tumorectomy or debulking of the primary or recurring tumor. Radiotherapy and adjuvant octreotide therapy were used with limited success, and chemotherapy added no benefit. Despite close follow-up and multifaceted adjuvant therapy, the mortality rate for thymic carcinoid tumors remains high.